Wall Street analysts forecast that Humana Inc (NYSE:HUM) will report $16.10 billion in sales for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Humana’s earnings, with the highest sales estimate coming in at $16.25 billion and the lowest estimate coming in at $16.01 billion. Humana posted sales of $14.21 billion during the same quarter last year, which would indicate a positive year over year growth rate of 13.3%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Humana will report full year sales of $64.33 billion for the current fiscal year, with estimates ranging from $63.75 billion to $64.84 billion. For the next financial year, analysts expect that the business will post sales of $70.37 billion, with estimates ranging from $70.04 billion to $71.01 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Humana.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $5.24 by $0.81. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm had revenue of $16.25 billion for the quarter, compared to analysts’ expectations of $15.88 billion. During the same period in the previous year, the firm posted $3.96 earnings per share. The business’s revenue was up 13.9% compared to the same quarter last year.

HUM has been the topic of several analyst reports. JPMorgan Chase & Co. boosted their price objective on Humana from $288.00 to $322.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. SunTrust Banks boosted their price objective on Humana to $340.00 and gave the stock a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley reduced their price objective on Humana from $331.00 to $315.00 and set an “overweight” rating on the stock in a research note on Friday, July 12th. Credit Suisse Group reduced their price objective on Humana from $352.00 to $315.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Finally, Citigroup reduced their price objective on Humana from $362.00 to $302.00 and set a “buy” rating on the stock in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the stock. Humana has a consensus rating of “Buy” and a consensus price target of $342.26.

Shares of HUM stock traded up $5.94 during trading hours on Tuesday, hitting $297.00. The stock had a trading volume of 605,000 shares, compared to its average volume of 1,168,642. The stock’s 50-day moving average price is $281.97 and its two-hundred day moving average price is $271.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75. Humana has a one year low of $225.65 and a one year high of $355.88. The stock has a market capitalization of $39.32 billion, a price-to-earnings ratio of 20.41, a PEG ratio of 1.26 and a beta of 0.85.

Several institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Maverick Capital Ltd. boosted its holdings in shares of Humana by 150.9% in the second quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock valued at $411,408,000 after purchasing an additional 932,778 shares during the period. Magnetar Financial LLC boosted its holdings in shares of Humana by 1,688.4% in the second quarter. Magnetar Financial LLC now owns 16,900 shares of the insurance provider’s stock valued at $4,484,000 after purchasing an additional 15,955 shares during the period. Verition Fund Management LLC boosted its holdings in shares of Humana by 64.8% in the second quarter. Verition Fund Management LLC now owns 24,127 shares of the insurance provider’s stock valued at $6,401,000 after purchasing an additional 9,490 shares during the period. HM Payson & Co. purchased a new stake in shares of Humana in the second quarter valued at approximately $131,000. Finally, OZ Management LP purchased a new stake in shares of Humana in the second quarter valued at approximately $87,255,000. 91.33% of the stock is currently owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading: How Do Front-End Loads Impact an Investment?

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.